SCHEMBL4670694

SCHEMBL4670694

O=C(C=C(O)c1nn[nH]n1)c1ccsc1Cc1ccccc1F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.34
MMEL1 Q495T6 2/20 0.33
CES1 P23141 1/20 0.33
NCEH1 Q6PIU2 1/20 0.33
ABL1 P00519 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.32
ERCC5 P28715 1/20 0.32
FEN1 P39748 1/20 0.32
HPGD P15428 1/20 0.32
MME P08473 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
RXFP1 Q9HBX9 1/20 0.32
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
KDM4E B2RXH2 1/20 0.31
AR P10275 1/20 0.31
GPR35 Q9HC97 1/20 0.31
HDAC3 O15379 1/20 0.30
HDAC4 P56524 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675657 0.86 CES1 (0.41) MMEL1CES1NCEH1ABL1ERCC5
SCHEMBL4673450 0.84 PTGDR2 (0.35) MAPK8MMEL1CES1NCEH1ABL1
SCHEMBL4675771 0.84 NPC1 (0.35) MAPK8ABL1HPGDMEN1KMT2A
SCHEMBL4670963 0.83 MMEL1 (0.34) MAPK8MMEL1CES1NCEH1ABL1
SCHEMBL4671226 0.83 HCAR2 (0.39) MAPK8MMEL1CES1NCEH1PTGDR2
SCHEMBL4676354 0.82 CES1 (0.34) MMEL1CES1NCEH1PTGDR2ERCC5
SCHEMBL4671646 0.82 LMNA (0.33) MMEL1CES1NCEH1ERCC5FEN1
SCHEMBL4675174 0.81 SLC40A1 (0.37) CES1NCEH1PTGDR2ERCC5FEN1
SCHEMBL4670732 0.80 MEN1 (0.34) MMEL1CES1NCEH1PTGDR2ERCC5
SCHEMBL4674267 0.80 CES1 (0.33) MMEL1CES1NCEH1HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 MAPK8 2178/4885MMEL1 1144/4885CES1 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.